Get started
Author

Dominick Y. Yeo

Observed name: Dominick Yeo
ORCID: 0009-0000-7460-2571
Observed ORCID: 0009-0000-7460-2571
OpenAlex ID: A5035751616
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody–Drug Conjugates
2021 · Stepan Chuprakov, Ayodele O. Ogunkoya, et al. · Bioconjugate Chemistry · 86
A metabolic inhibitor blocks cellular fucosylation and enables production of afucosylated antibodies
2024 · Pierre-André Gilormini, V. Narasimharao Thota, et al. · Proceedings of the National Academy of Sciences · 19
PDF
A Novel HER2-targeted Antibody–drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels
2020 · Robyn M. Barfield, Yun Cheol Kim, et al. · Molecular Cancer Therapeutics · 13
PDF
Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al. · Molecular Cancer Therapeutics · 4
PDF
Systematic LC/MS/MS Investigations for the IND-Enabling Extended Characterization of Antibody–Drug Conjugate Modifications
2018 · Thomas Linz, Dominick Yeo, et al. · Antibodies · 2
PDF
Data from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure 5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table 1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S4 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S1 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S6 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S3 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S7 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S8 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Figure S5 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S7 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Table S2 from Preclinical Characterization of XB010: A Novel Antibody–Drug Conjugate for the Treatment of Solid Tumors that Targets Tumor-Associated Antigen 5T4
2025 · Brian A. Mendelsohn, Kathleen R. Gogas, et al.
Works count: 33
Citation count: 124
H-index: 4
I10-index: 3
Year
Topic
Type